New combo therapy aims to tame rare inflammatory disease
NCT ID NCT07068165
First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tests whether adding lenalidomide to standard prednisone treatment can better control active IgG4-related disease, a rare condition causing swelling and damage in organs. About 198 adults will receive either low-dose lenalidomide plus prednisone, higher-dose lenalidomide plus prednisone, or prednisone alone for 52 weeks. The main goal is to see which group has fewer disease flare-ups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital, Beijing, Beijing 100050
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.